Biotech Values

[bellweather1]

(Not So)NICE

So Sad for patients, if you're correct about this,

in so much as that NICE is effectively serving as the British equivalent of the "Death Panels",

many believe the "Affordable Care Act" ultimately mandates.

And the hit patients will take is two pronged-

denial of currently available therapies, as well as future generations of such, which, at best, should see their development slowed.

Nevertheless, due to their critical value, I still believe high priority (i.e. survival critical) oncology products in unserved/underserved sectors are the most likely to sustain, if not thrive, in such a scorched earth context.

Certainly, we should expect to see an increasing number of capricious denials.

But in the final analysis, priority oncology products are still, to my mind, the most likely (on balance) to survive this purge, if only because their mission critical status will necessitate (and ultimately effect) a "compromise" with regulators.

Not sure that can be said with regard to any other high cost medical products.

Thus, I believe these should(and ultimately will, by and large) get the nod!